Application of deep learning algorithm for judicious use of anti-VEGF in diabetic macular edema
Abstract Diabetic Macular Edema (DME) is a major complication of diabetic retinopathy characterized by fluid accumulation in the macula, leading to vision impairment. The standard treatment involves anti-VEGF (Vascular Endothelial Growth Factor) therapy, but approximately 36% of patients do not resp...
Saved in:
| Main Authors: | Anwesa Mondal, Apurba Nandi, Subhasish Pramanik, Lakshmi Kanta Mondal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-87290-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema
by: Sanjay Kumar Mishra, et al.
Published: (2025-01-01) -
Metabolomics analysis uncovers metabolic changes and remodeling of anti-VEGF therapy on macular edema
by: Congcong Yan, et al.
Published: (2025-07-01) -
Comparison of intravitreal anti-VEGF agents and oral carbonic anhydrase inhibitors in the treatment of cystoid macular edema secondary to retinitis pigmentosa
by: Jia Liang, et al.
Published: (2024-12-01) -
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01) -
A machine learning model for predicting anatomical response to Anti-VEGF therapy in diabetic macular edema
by: Wenrui Lu, et al.
Published: (2025-05-01)